Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23967175 | 0.88 | CYP3A4 (0.67) | MAPTALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL594206 | 0.85 | MAPT (1.00) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL3044836 | 0.84 | MAPT (0.69) | MAPTALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL29057437 | 0.83 | MAPT (0.68) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL2074819 | 0.83 | MAPT (0.68) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL27783156 | 0.83 | AKR1C3 (0.85) | MAPTALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL24641954 | 0.82 | MAPT (0.83) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| Ammonia Solution, Strong SCHEMBL27607455 | 0.82 | MAPT (0.66) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL1393155 | 0.81 | AKR1C3 (0.68) | MAPTALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL315992 | 0.81 | ALDH1A1 (0.69) | MAPTALDH1A1LMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-113614087-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| CN-111718348-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)有限公司 | 2020-09-29 | — | — | CN | disclosed |
| US-20190084985-A1 | WEE1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2019-03-21 | — | — | US | disclosed |
| EP-3368538-A2 | WEE 1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | The Regents of The University of Colorado, A Body Corporate (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075629-A2 | WEE 1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075629-A2 | WEE 1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2316459-B1 | 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases | RIGEL PHARMACEUTICALS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947238-B2 | Wee1 kinase inhibitors and methods of making and using the same | WEE1, WEE2, MAP3K15 | MAPT 2360/4885ALDH1A1 4128/4885LMNA 2667/4885 |
| US-20190084985-A1 | WEE1 KINASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | WEE1, WEE2, MAP3K15 | MAPT 2360/4885ALDH1A1 4128/4885LMNA 2667/4885 |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | MAPT 25/4885ALDH1A1 3670/4885LMNA 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.